Loading company financials…
NYSE · Surgical & Medical Instruments & Apparatus · CIK 0000310764
$303.13
-8.33% · delayed 15 min
$115.67B market value
What this company does
STRYKER makes medical devices and equipment. It took in $25.12B last year, which makes it a large company. Of every dollar it sells, about 13 cents is left as profit.
Financial health
Strong finances across the board.
From STRYKER CORP's FY2025 annual filing · share price scored separately
Every check behind the three models, and what each one tests
of 9 checks passed
Measured against FY2024, from the 10-K
Improved: +11.2%
$22.59B to $25.12B
Improved: +8.5%
$2.99B to $3.25B
Improved: +22.8%
$3.49B to $4.28B
It makes a profit rather than burning through money.
$3.25B earned last year
Day-to-day operations generate real cash, not just accounting profit.
$5.04B cash from operations
A widely used bankruptcy-risk model places it well clear of distress.
Altman Z 4.37
Nothing in the filings stands out as a concern.
Filter by minute, hour, day or week
Loading price history…
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 11% a year for the next 10 years. Over the last 10 years it grew by about 20% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 13 cents of every dollar of sales as profit, earning $3.25B last year.
What it earns, what it keeps, and what it costs to run — all from the same filing
Whether the dividend is covered by what the business actually earns
It pays out 40 cents of every dollar of profit and keeps the rest, which leaves the payment comfortably covered. It paid out 25% of the cash its operations generated. It has paid in each of the last 12 years.
GoodNext payment expected around , projected from how regularly it has paid before rather than from a date the company has announced.
Figures from the FY2025 annual filing
Last year it earned $3.25B and generated $5.04B of cash from operations.
Reported annual figures
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Estimated from how often this has happened before, not a confirmed date.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Go deeper
Every figure above traces back to one of these filings.
Straight from SEC EDGAR — the original source for every figure above
| Filing | Filed | Covers to |
|---|---|---|
| Quarterly report(10-Q) | 2026-07-31 | 2026-06-30 |
| Major event announcement(8-K) | 2026-07-30 | 2026-07-30 |
Financial figures are from SYK's 10-K for fiscal year 2025 (period ending 2025-12-31), reported under the US GAAP taxonomy. View the source filing.
Nine yes-or-no tests of whether this year's finances improved on last year's.
4.37
In the safe zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-2.62
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Deteriorated: +21.9%
$12.19B to $14.86B
Improved: +9.8%
$3.65B to $4.01B
4 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Nothing here reads the management commentary, which is where a company explains its own numbers.
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 8% and 13%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 1.8% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
Slowly. Sales grew 11.2% last year.
No. At its current cash flow it could clear its debt in about 2.3 years. For every $1 it owes, it owns $1.88 in assets.
Expensive. Investors pay $35.6 for every $1 of yearly profit, so a lot of future growth is already priced in.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
At a glance
| Major event announcement(8-K) | 2026-06-26 | 2026-06-26 |
| Major event announcement(8-K) | 2026-05-20 | 2026-05-15 |
| Quarterly report(10-Q) | 2026-05-11 | 2026-03-31 |
| Major event announcement(8-K) | 2026-05-08 | 2026-05-06 |
| Major event announcement(8-K) | 2026-04-30 | 2026-04-30 |
| Major event announcement (amended)(8-K/A) | 2026-04-09 | 2026-03-11 |
| Shareholder voting information(DEF 14A) | 2026-03-23 | 2026-05-06 |
| Major event announcement(8-K) | 2026-03-23 | 2026-03-23 |
| Major event announcement(8-K) | 2026-03-12 | 2026-03-12 |
| Major event announcement(8-K) | 2026-03-11 | 2026-03-11 |
| Annual report(10-K) | 2026-02-11 | 2025-12-31 |
| Major event announcement(8-K) | 2026-01-29 | 2026-01-29 |
| Major event announcement(8-K) | 2025-12-04 | 2025-12-04 |
| Quarterly report(10-Q) | 2025-10-31 | 2025-09-30 |
| Major event announcement(8-K) | 2025-10-30 | 2025-10-30 |
| Quarterly report(10-Q) | 2025-08-01 | 2025-06-30 |
| Major event announcement(8-K) | 2025-07-31 | 2025-07-31 |
| Major event announcement(8-K) | 2025-05-13 | 2025-05-08 |
Coverage from the last 30 days
Schedule update: Stryker to participate in the 2026 Wells Fargo Healthcare Conference
Yahoo Finance ·
Stryker (SYK) is Buying ZuriMED. Can FiberLocker Strengthen its Shoulder Portfolio?
Yahoo Finance ·
Intuitive Surgical Vs. Stryker: Wall Street Loves Both But One Has a Quiet Advantage That Will Make Investors Money
Yahoo Finance ·
Stryker Launches FDA-Cleared Apple Vision Pro Surgical App
Yahoo Finance ·
Medical Devices & Supplies - Diversified Stocks Q2 Teardown: Stryker (NYSE:SYK) Vs The Rest
Yahoo Finance ·
Sector Update: Healthcare Stocks Rise Tuesday Afternoon
Yahoo Finance ·
Stryker (SYK) Wins FDA Nod And Completes First Procedure With New Surgery Software
Yahoo Finance ·
Stryker to add rotator cuff repair tech with ZuriMED buy
Yahoo Finance ·
Stryker to Acquire ZuriMED to Expand Its Shoulder Care Portfolio
Yahoo Finance ·
Stryker introduces first of its kind FDA-authorized surgical application for Apple Vision Pro with hip arthroscopy case at nationally recognized academic medical center
Yahoo Finance ·
Is Stryker Stock Underperforming the Nasdaq?
Yahoo Finance ·
Stryker (SYK) Stock Looks Like A Bargain Near Fair Value
Yahoo Finance ·
Primary sources and further research